1. A rocking base assembly for supporting a reformer exercise apparatus having an elongated rectangular frame adapted to be positioned parallel to a flat support surface, the frame having with head and foot ends, the assembly comprising:
a pair of rocker bases each having a platform portion for supporting one end of the reformer frame and a rocker member beneath the platform portion, the rocker member having a bottom curved surface portion.
2. The assembly according to claim 1 wherein the rocker member is fastened to the platform portion.
3. The assembly according to claim 1 wherein the rocker member is an integral part of the platform portion.
4. The assembly according to claim 1 wherein the bottom curved surface portion of the rocker member merges with straight end portions.
5. The assembly according to claim 1 wherein the platform portion further comprises a guide rail on an upper surface thereof for positioning the reformer frame thereon.
6. The assembly according to claim 1 further comprising a pair of removable stop blocks each having a central recess having a bottom shape complementary to that of one of the straight end portions of the rocker member and having at least one upright side wall.
7. The assembly according to claim 6 wherein each block has a pair of upright side walls with the central recess therebetween.
8. The assembly according to claim 1 further comprising a pair of removable stop blocks for each rocker base, each block having a central recess having a bottom shape complementary to that of one of the straight end portions of the rocker member and at least one upright side wall.
9. A reformer exercise apparatus comprising:
a generally rectangular frame having a head end and a foot end and having parallel spaced tracks therebetween supporting a movable carriage thereon; and
a first rocking support assembly supporting the head end of the frame and a second rocking support assembly supporting the foot end of the frame.
10. The apparatus according to claim 9 wherein each rocking support assembly has a generally flat platform portion engaging and supporting one of the head and foot ends of the frame and a rocker member beneath the platform, wherein the rocker member has a bottom curved surface portion between straight end portions.
11. The apparatus according to claim 10 wherein the curved surface portion is arcuate having a radius of between 24 and 48 inches.
12. The apparatus of claim 9 wherein each rocking support assembly is removable from the reformer frame.
13. The apparatus of claim 10 wherein each support assembly further comprises a pair of removable blocks each having a central recess having a bottom shape complementary to that of end portions of the rocker member and having at least one upright side wall engagable with the platform portion.
14. The apparatus according to claim 13 wherein each block has a pair of upright side walls with the central recess therebetween.
15. The apparatus according to claim 10 wherein the platform portion is adapted to hold thereon a ballast weight.
16. A kit for changing a conventional reformer apparatus having four legs into a rocking reformer apparatus, the kit comprising two rocking support base assemblies, each assembly having a rocker platform portion adapted to be positioned beneath and support two of the legs and a rocking member beneath the platform portion, wherein the rocker member has a bottom curved surface portion between straight end portions, and a pair of removable blocks each having a central recess shaped complementary to that of one end portion of the rocker member.
17. The kit according to claim 16 wherein the platform portion has a pair of recesses in an upper surface of the platform portion each shaped to receive one of the four legs of a reformer apparatus therein.
18. The kit according to claim 16 wherein the platform portion has an upright peg extending from an upper surface of the platform portion for receiving a ballast weight.
19. The kit according to claim 16 wherein each block has at least one side wall adapted to contact the platform portion and a support surface supporting the rocker member when the end portion of the rocker member is positioned in the central recess. of the block.
20. The kit according to claim 19 wherein each block has two spaced side walls.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of Formula (I):
or a pharmaceutically acceptable salt or ester thereof, wherein:
Ar1 and Ar2 are each independently aryl, wherein each said aryl is substituted with one or more independently selected groups Y1;
wherein each said Y1 attached to Ar1 and Ar2 is independently selected from the group consisting of \u2014(C2-C20) alkyl, cycloalkyl, halo, haloalkyl, benzyl, aryl, \u2014O-aryl, \u2014S-aryl, \u2014S(O)2-alkyl, \u2014S(O)2-cycloalkyl, \u2014S(O)2-aryl -alkylene-CN, \u2014CN, \u2014C(O)-alkyl, \u2014C(O)-aryl, \u2014C(O)-haloalkyl, \u2014O-haloalkyl, \u2014O-alkylene-C(O)OH, \u2014S-alkyl, \u2014S-haloalkyl, -alkylene-OH, -alkylene-C(O)\u2014O-alkyl, \u2014O-alkylene-aryl, and \u2014N(R5)2,
wherein said aryl, the aryl portion of said O-aryl, the aryl portion of said \u2014S-aryl, the aryl portion of said S(O)2-aryl, the aryl portion of said benzyl, the aryl portion of said C(O)-aryl, and the aryl portion of said \u2014O-alkylene-aryl of Y1 are unsubstituted or substituted with one or more groups Z:
X is selected from the group consisting of \u2014C(R2)\u2550C(R2)-aryl and \u2014(C(R2)2)s-aryl wherein s is 0, 1, or 2,
wherein the aryl portion of said \u2014C(R2)\u2550C(R2)-aryl and the aryl portion of said \u2014(C(R2)2)s-aryl of X are unsubstituted or substituted with one or more groups Y1:
wherein each said Y1, when attached to said aryl portion of said \u2014C(R2)\u2550C(R2)-aryl or said aryl portion of said \u2014(C(R2)2)s-aryl of X, is independently selected from the group consisting of alkyl, cycloalkyl, halo, haloalkyl, benzyl, aryl, \u2014O-aryl, \u2014S-aryl, \u2014S(O)2-alkyl, \u2014S(O)2-cycloalkyl, \u2014S(O)2-aryl, -alkylene-CN, \u2014CN, \u2014N(R2)C(O)-alkyl, \u2014N(R2)C(O)\u2014N(R2)2, \u2014OH, \u2014O-alkyl, \u2014O-haloalkyl, \u2014O-alkylene-C(O)OH, \u2014S-alkyl, \u2014S-haloalkyl, -alkylene-OH, -alkylene-C(O)\u2014O-alkyl, \u2014O-alkylene-aryl, and \u2014N(R5)2,
wherein said aryl, the aryl portion of said O-aryl, the aryl portion of said \u2014S-aryl, the aryl portion of said \u2014S(O)2-aryl, the aryl portion of said benzyl, the aryl portion of said C(O)-aryl, and the aryl portion of said \u2014O-alkylene-aryl of Y1 are unsubstituted or substituted with one or more groups Z;
each R1 is independently selected from the group consisting of alkyl, haloalkyl, -alkylene-N(R5)2, -alkylene-OR2, alkylene-N3, -alkylene-CN, and alkylene-O\u2014S(O)2-alkyl: or
two R1 groups attached to the same ring carbon atom form a carbonyl group;
p is 0, 1, 2, 3, or 4:
each R2 is independently H, alkyl, or aryl,
wherein said aryl of R2 is unsubstituted or substituted with one or more groups Y1;
wherein each Y1, when attached to said aryl of R2, is independently selected from the group consisting of alkyl, cycloalkyl, halo, haloalkyl, benzyl, aryl, \u2014O-aryl, \u2014S-aryl, \u2014S(O)2-alkyl, \u2014S(O)2-cycloalkyl, \u2014S(O)2-aryl, -alkylene-CN, \u2014CN, \u2014C(O)-alkyl, \u2014C(O)-aryl, \u2014C(O)-haloalkyl, \u2014C(O)O-alkyl, \u2014N(R2)C(O)-alkyl, \u2014N(R2)C(O)\u2014N(R2)2, \u2014OH, \u2014O-alkyl, \u2014O-haloalkyl, \u2014O-alkylene-C(O)OH, \u2014S-alkyl, \u2014S-haloalkyl, -alkylene-OH, -alkylene-C(O)\u2014O-alkyl, \u2014O-alkylene-aryl, and \u2014N(R5)2,
wherein said aryl, the aryl portion of said \u2014O-aryl, the aryl portion of said \u2014S-aryl, the aryl portion of said \u2014S(O)2-aryl, the aryl portion of said benzyl, the aryl portion of said \u2014C(O)-aryl, and the aryl portion of said \u2014O-alkylene-aryl of Y1 are unsubstituted or substituted with one or more groups Z;
each R5 is independently selected from the group consisting of H, alkyl, aryl, \u2014S(O)2-alkyl, \u2014S(O)2-cycloalkyl, \u2014S(O)2-aryl, \u2014C(O)\u2014N(R2)2, \u2014C(O)-alkyl, and -alkylene-OH.
wherein said aryl and the aryl portion of said \u2014S(O)2-aryl of R5 are unsubstituted or substituted with one or more Z groups;
and
each Z is independently selected from the group consisting of alkyl, halo, haloalkyl, \u2014OH, \u2014O-alkyl, and \u2014CN.
2. A compound of claim 1, or a pharmaceutically acceptable salt or ester thereof, wherein:
Ar1 and Ar2 are independently \u2014(C6-C10)aryl,
wherein said (Co\u2014C10)aryl is substituted with one or more groups Y1;
wherein each Y1 attached to Ar1 and Ar2 is independently selected from the group consisting of (C2-C6)alkyl. (C3-C10)cycloalkyl, halo, (C1-C6)haloalkyl, benzyl, (C6-C10)aryl, (C2-C10)heteroaryl, \u2014O\u2014(C6-C10)aryl, \u2014S\u2014(C6-C10)aryl, \u2014S(O)2\u2014(C1-C6)alkyl, \u2014S(O)2\u2014(C3-C10)cycloalkyl, \u2014S(O)2\u2014(C6-C6)alkylene-CN, \u2014CN, \u2014C(O)\u2014(C1-C6)alkyl, \u2014C(O)\u2014(C1-C6)haloalkyl, \u2014C(O)O\u2014(C1-C6)alkyl, \u2014N(R2)C(O)\u2014(C1-C10)aryl, \u2014C(O)\u2014(C1-C6)haloalkyl, \u2014OH, \u2014O\u2014(C1-C6)alkyl, \u2014O\u2014(C1-C6)haloalkyl, \u2014O\u2014(C1-C6)alkylene-C(O)OH, \u2014S\u2014(C1-C6)alkyl, \u2014S\u2014(C1-C6)haloalkyl, \u2014(C1-C6)alkylene-OH, \u2014(C1-C6)alkylene-C(O)\u2014O\u2014(C1-C10)alkyl \u2014O\u2014(C1-C6)alkylene-(C6-C10)aryl, and \u2014N(R5)2,
wherein said (C6-C10)aryl, the (C6-C10)aryl portion of said \u2014O\u2014(C6-C10)aryl, the (C6-C10)aryl portion of said \u2014S\u2014(C6-C10)aryl, the (C6-C10)aryl portion of said \u2014S(O)2\u2014(C6-C10)aryl, said benzyl, the (C6-C10)aryl portion of said \u2014C(O)\u2014(C6-C10)aryl, and the (C6-C10)aryl portion of said \u2014O\u2014(C1-C6)alkylene-(C6-C10)aryl, of Y1 are unsubstituted or substituted with one or more groups Z;
X is selected from the group consisting of and \u2014(C(R2)2)s\u2014(C6-C10)aryl wherein s is 0, 1 or 2,
wherein the (C6-C10)aryl portion of said \u2014C(R2)\u2550C(R2)\u2014(C6-C10)aryl and the (C6-C10)aryl portion of said \u2014(C(R3)2)s(C6-C10)aryl of X are unsubstituted or substituted with one or more groups Y1;
wherein each Yt, when attached to said aryl portion of said \u2014C(R2)\u2550C(R2)\u2014(C6-C10)aryl or said aryl portion of said \u2014(C(R2)2)s\u2014(C6-C10)aryl of X, is independently selected from the group consisting of (C1-C6)alkyl, (C3-C10)cycloalkyl, halo, (C1-C6)haloalkyl, benzyl, (C6-C10)aryl, (C2-C10)heteroaryl, \u2014O\u2014(C6-C10)aryl, \u2014S\u2014(C6-C10)aryl, \u2014S(O)2\u2014(C1-C6)alkyl, \u2014S(O)2\u2014(C3-C10)cycloalkyl, \u2014S(O)2\u2014(C6-C10)aryl, \u2014(C1-C6)alkylene-CN, \u2014CN, \u2014CN, \u2014C(O)\u2014(C1-C6)alkyl, \u2014C(O)\u2014(C6-C10)aryl, \u2014C(O)\u2014(C1-C6)haloalkyl, \u2014C(O)O\u2014(C1-C6)alkyl, \u2014N(R2)C(O)\u2014(C1-C6)alkyl, \u2014N(R2)2, \u2014OH, \u2014O\u2014(C1-C6)alkyl, \u2014O\u2014(C1-C6)haloalkyl, \u2014O\u2014(C1-C6)alkylene-C(O)OH, \u2014S\u2014(C1-C6)alkyl, \u2014S\u2014(C1-C6)haloalkyl, \u2014(C1-C6)alkylene-OH, \u2014(C1-C6)alkylene-C(O)\u2014O\u2014(C1-C6)alkyl, \u2014O\u2014(C1-C6)alkylene-(C6-C10)aryl, and \u2014N(R5)2,
wherein said (C6-C10)aryl, the (C6-C10)aryl portion of said \u2014O\u2014(C6-C10)aryl, the (C6-C10)aryl portion of said \u2014S\u2014(C6-C10)aryl, the (C6-C10)aryl portion of said \u2014S(O)2\u2014(C6-C10)aryl, said benzyl, the (C6-C10)aryl portion of said \u2014C(O)\u2014(C6-C10)aryl, and the (C6-C10)aryl portion of said \u2014O\u2014(C1-C6)alkylene-(C6-C10)aryl of Y1 are unsubstituted or substituted with one or more groups Z:
each R1 is independently selected from the group consisting of (C1-C6)alkyl, (C1-C6)haloalkyl, \u2014(C1-C6)alkylene-N(R5)2, \u2014(C1-C6)alkylene-OR2, \u2014(C1-C6)alkylene-N3, -(C1-C6)alkylene-CN, and (C1-C6)alkylene-O\u2014S(O)2\u2014(C1-C6)alkyl; or
two R groups attached to the same ring carbon atom form a carbonyl group;
p is 0, 1, 2, 3, or 4;
each R2 is independently H. (C1-C6)alkyl, or (C6-C10)aryl,
wherein said (C6-C10)aryl of R2 is unsubstituted or substituted with one or more groups Y1;
wherein each Y1, when attached to said (C6-C10)aryl of R2, is independently selected from the group consisting of (C1-C6)alkyl, (C3-C10)cycloalkyl, halo, (C1-C10)haloalkyl, benzyl, (C1-C10)aryl, (C2-C10)heteroaryl, \u2014O\u2014(C6-C10)aryl, \u2014S\u2014(C6-C10)aryl, \u2014S(O)2\u2014(C1-C6)alkyl, \u2014S(O)2\u2014(C3-C10)cycloalkyl, \u2014S(O)2\u2014(C6-C10)aryl, \u2014(C1-C6)alkylene-CN, \u2014CN, \u2014C(O)\u2014(C1-C6)alkyl, \u2014C(O)\u2014(C6-C10)aryl, \u2014C(O)\u2014(C1-C6)haloalkyl, \u2014C(O)O\u2014(C1-C6)alkyl, \u2014N(R2)C(O)\u2014(C1-C6)alkyl, \u2014N(R2)C(O)\u2014N(R2)2, \u2014OH, \u2014O\u2014(C1-C6)alkyl, \u2014O\u2014(C1-C6)haloalkyl, \u2014O\u2014(C1-C6)alkylene-C(O)OH, \u2014S\u2014(C1-C6)alkyl, \u2014S\u2014(C1-C6)haloalkyl, \u2014(C1-C6)alkylene-OH. \u2014(C1-C10)alkylene-C(O)\u2014O\u2014(C1-C6)alkyl, \u2014O\u2014(C1-C6)alkylene-(C6-C10)aryl, and \u2014N(R5)2,
wherein said (C6-C10)aryl, the (C6-C10)aryl portion of said \u2014O\u2014(C6-C10)aryl, the (C6-C10)aryl portion of said \u2014S\u2014(C6-C10)aryl, the (C6-C10)aryl portion of said \u2014S(O)2\u2014(C6-C10)aryl, said benzyl, the (C6-C10)aryl portion of said \u2014C(O)\u2014(C6-C10)aryl, and the (C6-C10)aryl portion of said \u2014(O)\u2014(C1-C6)alkylene-(C6-C10)aryl of Y1 are unsubstituted or substituted with one or more groups Z;
each R5 is independently selected from the group consisting of H, (C1-C6)alkyl, (C6-C10)aryl, \u2014S(O)2\u2014(C1-C6alkyl, \u2014S(O)2\u2014(C3-C10)cycloalkyl, \u2014S(O)2-aryl, \u2014C(O)\u2014N(R2)2, \u2014C(O)\u2014(C1-C6)alkyl, and \u2014(C1-C10)alkylene-OH,
wherein said (C6-C10)aryl and the (C6-C10)aryl portion of said \u2014S(O)2\u2014(C6-C10)aryl of R5 are unsubstituted or substituted with one or more Z groups;
each Z is independently selected from the group consisting of (C1-C6)alkyl, halo, (C1-C6)haloalkyl, \u2014OH, \u2014O\u2014(C1-C6)alkyl, and \u2014CN.
3. A compound of claim 1, or a pharmaceutically acceptable salt or ester thereof, wherein:
Ar2 is a phenyl substituted with two independently selected Y1 groups.
4. A compound of claim 3, or a pharmaceutically acceptable salt or ester thereof, wherein:
Ar2 is a phenyl substituted with two independently selected Y1 groups at the 2- and 4-position.
5. A The compound of claim 4, or a pharmaceutically acceptable salt or ester thereof, wherein:
Ar1 is a phenyl substituted with one Y1 group at the 4-position.
6. A compound according to claim 1, or a pharmaceutically acceptable salt or ester thereof, wherein X is \u2014(C(R2)2)s-aryl, and said aryl of X is unsubstituted or substituted with one or more independently selected Y1 groups.
7. A compound according to claim 6, wherein s is 0.
8. A compound according to claim 1, or a pharmaceutically acceptable salt or ester thereof, wherein:
X is \u2014C(R2)\u2550C(R2)-aryl, and said aryl of X is unsubstituted or substituted with one or more independently selected Y1 groups.
9. A compound according to claim 1, or a pharmaceutically acceptable salt or ester thereof, having the following Formula (IA):
10. A compound according to claim 1, or a pharmaceutically acceptable salt or ester thereof, having the following Formula (IB):
11. A compound according to claim 1, or a pharmaceutically acceptable salt or ester thereof, having the following Formula (IC):
12. A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
13. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Ar2 is a phenyl substituted with 1 Y1 group.
14. A compound of claim 5, or a pharmaceutically acceptable salt or ester thereof, wherein each Y1 is independently selected from the group consisting of halo, \u2014OH, \u2014CN, \u2014(C2-C6)alkyl, haloalkyl, and \u2014O-haloalkyl.
15. A compound of claim 5, or a pharmaceutically acceptable salt or ester thereof, wherein p is 0.
16. A compound of claim 5, or a pharmaceutically acceptable salt or ester thereof, wherein p is 0, 1, 2, 3, or 4, and each R1 is independently selected from the group consisting of alkyl and haloalkyl.
17. A compound of claim 5, or a pharmaceutically acceptable salt or ester thereof, wherein p is 2 and two R groups bound to the same ring carbon atom are taken together to form a carbonyl group.
18. A compound according to claim 6, or a pharmaceutically acceptable salt or ester thereof, wherein s is 1.
19. A compound according to claim 6, or a pharmaceutically acceptable salt or ester thereof, wherein s is 2.
20. A compound according to claim 6, or a pharmaceutically acceptable salt or ester thereof, wherein X is \u2014(C(R2)2)s-phenyl, and said phenyl of X is unsubstituted or substituted with one or more Y1 groups independently selected from the group consisting of halo, \u2014OH, \u2014CN, alkyl, haloalkyl, phenyl, \u2014O-alkyl, \u2014O-haloalkyl, \u2014S-phenyl, \u2014S-alkyl, \u2014S-haloalkyl, and \u2014S-phenyl.
21. A compound according to claim 8, or a pharmaceutically acceptable salt or ester thereof, wherein X is \u2014C(R2)\u2550C(R2)-phenyl, and said phenyl of X is unsubstituted or substituted with one or more Y1 groups independently selected from the group consisting of halo, \u2014OH, \u2014CN, alkyl, haloalkyl, phenyl, \u2014O-alkyl, \u2014O-haloalkyl, \u2014S-phenyl, \u2014S-alkyl, \u2014S-haloalkyl, and \u2014S-phenyl.
22. A composition comprising at least one compound according to claim 1, or a pharmaceutically acceptable salt of said at least one compound, and at least one pharmaceutically acceptable carrier.
23. A composition comprising at least one compound according to claim 12, or a pharmaceutically acceptable salt of said at least one compound, and at least one pharmaceutically acceptable carrier.
24. A compound of the following formula;
or a pharmaceutically acceptable salt thereof.
25. A composition comprising the compound of claim 24, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
26. A compound of the following formula:
or a pharmaceutically acceptable salt thereof.
27. A composition comprising the compound of claim 26, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
28. A compound of the following formula:
or a pharmaceutically acceptable salt thereof.
29. A composition comprising the compound of claim 28, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
30. A compound of the following formula:
or a pharmaceutically acceptable salt thereof.
31. A composition comprising the compound of claim 30, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
32. A compound of the following formula:
or a pharmaceutically acceptable salt thereof.
33. A composition comprising the compound of claim 32, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
34. A compound of the following formula:
or a pharmaceutically acceptable salt thereof.
35. A composition comprising the compound of claim 34, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
36. A compound of the following formula:
or a pharmaceutically acceptable salt thereof.
37. A composition comprising the compound of claim 36, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
38. A compound of the following formula:
or a pharmaceutically acceptable salt thereof.
39. A composition comprising the compound of claim 38, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
40. A compound of the following formula:
or a pharmaceutically acceptable salt thereof.
41. A composition comprising the compound of claim 40, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
42. A compound of the following formula:
or a pharmaceutically acceptable salt thereof.
43. A composition comprising the compound of claim 42, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
44. A compound of the following formula:
or a pharmaceutically acceptable salt thereof.
45. A composition comprising the compound of claim 44, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
46. A compound of the following formula:
or a pharmaceutically acceptable salt thereof.
47. A composition comprising the compound of claim 46, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
48. A compound of the following formula:
or a pharmaceutically acceptable salt thereof.
49. A composition comprising the compound of claim 48, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
50. A compound according to any one of claims 12 or 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, or 48, or a pharmaceutically acceptable salt thereof, in isolated or purified form.